Yüklüyor......
Past, Current, and Future of Immunotherapies for Prostate Cancer
Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate canc...
Kaydedildi:
| Yayımlandı: | Front Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6749031/ https://ncbi.nlm.nih.gov/pubmed/31572678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00884 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|